LAUSR

Characterizing the severity of nonalcoholic fatty liver disease (NAFLD) is essential for risk stratification and optimizing the management plan. For long, a liver biopsy was the sole option to diagnose NAFLD patients with nonalcoholic steatohepatitis (NASH) who are at risk of progression and those with advanced fibrosis who are at a higher risk of incident liver-related morbidity and mortality.1 However, the high prevalence of NAFLD and the invasive nature of liver biopsy has placed a barrier for the diagnosis of NASH.1 This bottleneck thankfully fueled the need to develop several non-invasive approaches to identify patients with NAFLD who are at increased risk of developing liver-related morbidity and mortality without the need for receiving a liver biopsy assessment.